-
公开(公告)号:US20200002330A1
公开(公告)日:2020-01-02
申请号:US16309076
申请日:2017-06-12
Applicant: NOVARTIS AG
Inventor: Zhuoliang CHEN , Jorge Garcia FORTANET , Rajesh KARKI , Matthew J. LAMARCHE , Dyuti MAJUMDAR , Lawrence Blas PEREZ , Martin SENDZIK , Troy Douglas SMITH , Fan YANG , Bing YU
IPC: C07D471/04 , C07D513/04 , C07D495/04 , C07D487/04 , C07D403/14 , C07D519/00 , C07D455/02 , C07D401/14
Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
-
公开(公告)号:US20240199609A1
公开(公告)日:2024-06-20
申请号:US18523565
申请日:2023-11-29
Applicant: NOVARTIS AG
Inventor: Zhuoliang CHEN , Jorge Garcia FORTANET , Rajesh KARKI , Matthew J. LAMARCHE , Dyuti MAJUMDAR , Lawrence Blas PEREZ , Martin SENDZIK , Troy Douglas SMITH , Fan YANG , Bing YU
IPC: C07D471/04 , C07D401/14 , C07D403/14 , C07D455/02 , C07D487/04 , C07D495/04 , C07D513/04 , C07D519/00
CPC classification number: C07D471/04 , C07D401/14 , C07D403/14 , C07D455/02 , C07D487/04 , C07D495/04 , C07D513/04 , C07D519/00
Abstract: The present invention relates to compounds of formula I:
in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.-
公开(公告)号:US20210323956A1
公开(公告)日:2021-10-21
申请号:US17268512
申请日:2019-08-12
Applicant: Novartis AG
Inventor: Christopher ADAIR , Katsumasa NAKAJIMA , Rukundo NTAGANDA , Julien PAPILLON , Troy Douglas SMITH
IPC: C07D417/12 , A61K45/06
Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.
-
公开(公告)号:US20210300919A1
公开(公告)日:2021-09-30
申请号:US17130374
申请日:2020-12-22
Applicant: Novartis AG
Inventor: Zhuoliang CHEN , Jorge Garcia FORTANET , Rajesh KARKI , Matthew J. LAMARCHE , Dyuti MAJUMDAR , Lawrence Blas PEREZ , Martin SENDZIK , Troy Douglas SMITH , Fan YANG , Bing YU
IPC: C07D471/04 , C07D513/04 , C07D495/04 , C07D487/04 , C07D401/14 , C07D519/00 , C07D455/02 , C07D403/14 , A61P35/00
Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
-
-
-